The Future of Myeloproliferative Neoplasm Treatment

EP: 1.Myeloproliferative Neoplasms: Essential Thrombocythemia

EP: 2.Managing Patients with Essential Thrombocythemia

EP: 3.Myeloproliferative Neoplasms: Polycythemia Vera

EP: 4.Treatment Options for Polycythemia Vera

EP: 5.PTG-300 Therapy for Phlebotomy-Dependent Polycythemia Vera

EP: 6.Assessing Symptom Burden and Quality-of-Life for Myeloproliferative Neoplasms

EP: 7.Myeloproliferative Neoplasms: Myelofibrosis

EP: 8.Risk Stratification for Myelofibrosis

EP: 9.Ruxolitinib in Myelofibrosis Treatment and the COMFORT Trials

EP: 10.New JAK Inhibitors in Myelofibrosis Treatment

EP: 11.Efficacy and Safety of JAK Inhibitors for Myelofibrosis

EP: 12.Momelotinib in Myelofibrosis Treatment: Updates from ASCO 2022

EP: 13.Novel Agents Under Investigation for Myelofibrosis

EP: 14.Management of Accelerated Phase Myeloproliferative Neoplasms

EP: 15.Clinical Scenario: A 67-Year-Old with Myelofibrosis

EP: 16.Myelofibrosis Treatment Approaches after Disease Progression

EP: 17.Clinical Scenario: A 74-Year-Old with Cytopenic Myelofibrosis

Now Viewing

EP: 18.The Future of Myeloproliferative Neoplasm Treatment

Rami Komrokji, MD: Before we conclude, I’ll ask everyone for their final thoughts. Jeanne?

Jeanne Palmer, MD: We’ve been able to review a lot of information today. In ET [essential thrombocythemia], PV [polycythemia vera], and MF [myelofibrosis], we have a lot of therapies coming down the pipeline and approved, which has changed the way we look at and treat these patients. It’s important to make sure that we’re thinking of the big picture and learning about these new therapies and utilizing them.

Rami Komrokji, MD: Absolutely. Ruben?

Ruben Mesa, MD: I’m incredibly hopeful. We’ve evolved from the first 15 years of my career, where we were trying to use drugs from other indications that largely weren’t overly active, to 15 years of drugs specifically designed to try to have an impact in MPNs [myeloproliferative neoplasms]. We’ve made great progress. We now have 4 new approved drugs, between ruxolitinib, fedratinib, pacritinib, and ropegylated interferon. We have a raft of others, both a single agent and a combination in phase 3 trials. All of that will benefit our patients to a much greater degree.

We’re learning from our colleagues. We’ve just come from the ASCO [American Society of Clinical Oncology] annual meeting. With most diseases, we don’t treat with a single drug. Whether we’re talking about solid tumors, myeloma, CLL [chronic lymphocytic leukemia], or lymphoma, it’s combinations, subtlety, and precision medicine that’s mindful of the patient, their circumstance, health equity, and the biology of their disease. It’s exciting to see MPNs mature, like the other diseases have matured.

Rami Komrokji, MD: Absolutely. And Jamile?

Jamile Shammo, MD, FACP, FASCP: I’d like to say that perhaps the age of stagnation is going to be over very soon, because there are a lot of new drugs, new developments, and a lot of hope. It’s exciting.

Rami Komrokji, MD: Thank you for joining us. We hope you found this OncLive® Peer Exchange discussion to be useful and valuable to the treatment of your patients with myeloproliferative neoplasms.

Transcript edited for clarity.